SEI Investments’s UroGen Pharma URGN Stock Holding History

SEI Investments’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-815	Closed	-$38K	–	2987
2018 Q4	$38K	Hold	815	–	–	﹤0.01%	2402
2018 Q3	$38K	Buy	+815	New	+$37.9K	﹤0.01%	2292

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SEI Investments's URGN Position: Q1 2019 in Review

SEI Investments sold out of UroGen Pharma (URGN) in Q1 2019, closing a stake of 815 shares — an estimated $38K sold.

SEI Investments first reported a position in URGN in Q3 2018 and held it in 2 quarters. The position peaked at $38K in Q4 2018. 74 funds tracked by Wall St. Rank hold URGN as of Q1 2019.

SEI Investments reported no remaining UroGen Pharma position as of Q1 2019 after selling out during the quarter.
SEI Investments sold 815 UroGen Pharma shares in Q1 2019, an estimated $38K.
SEI Investments first reported a position in UroGen Pharma in Q3 2018 and held it in 2 quarters.
SEI Investments's UroGen Pharma position peaked at $38K in Q4 2018.
74 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2019.

Based on SEI Investments's 13F filing for Q1 2019, filed 15 May 2019.